Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...
Stocktwits on MSN57m
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
Lena Zewdu Feleke is a senior at Martin Luther King Jr. Magnet High School and a student from the School for Science and Math ...
Most employers are expecting to hire this year, according to BioSpace data and Recruitment Manager Greg Clouse, who noted ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...
A recent executive order from President Donald J. Trump pausing trillions of dollars in federal grant and loan funding has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback